ClinicalTrials.gg

Program

AXT-1003

A development code. Also written as “AXT-1003, Enzalutamide”.

Its studies are mostly in Lymphoma, Non-Hodgkin, led by Axter Therapeutics (Beijing).

Furthest: phase 1, since Jul 12, 20233 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Axter Therapeutics (Beijing)32 open or runningphase 1since Jul 12, 2023Jul 12, 2023Mar 2027phase 1 · NCT06484985

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 12, 2023First study: phase 1 study in RecurrenceFirst studyNCT05965505 · 1 enrolled · China
  2. Jun 26, 2024Phase 1 study in Lymphoma, Non-HodgkinNCT06484985 · 78 planned · China
  3. Oct 8, 2026Phase 1 study in mCRPCNCT07897071 · 105 planned · China

Ahead

  1. Mar 2027Primary completion: phase 1 study in Lymphoma, Non-HodgkinNCT06484985
  2. Aug 2028Primary completion: phase 1 study in mCRPCNCT07897071

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07897071mCRPC · China1RecruitingAug 2028105
NCT06484985Lymphoma, Non-Hodgkin · China1RecruitingMar 202778
NCT05965505Recurrence · China1TerminatedSep 5, 20231

How it is read

Names in the registry

  • “AXT-1003, Enzalutamide”, 2 entries
  • “AXT-1003”, 2 entries

Codes read as this program: AXT1003.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.